Search PubMed⌕ Search

Biomedical subjects

P Zündorf

Publications and source records attributed to P Zündorf.

6 recordsLinked to original sources
PubMed1985

Acemetacin in the treatment of rheumatic diseases: an open, multi-centre trial.

An open, multi-centre trial was carried out to assess the efficacy and tolerance of acemetacin in the treatment of patients suffering from various rheumatic diseases. The patients were treated by general practitioners for a maximum period of 6 weeks with a daily dose of 60 mg acemetacin 3-times daily. Assessments were made before, during and after treatment of pain parameters, joint function and swelling, and records kept of any adverse events reported. At the end of treatment, the physician made an overall assessment of response. Data from 760 patients were analyzed and showed 'very good' or 'good' improvement in 55% and 28.5% of patients, respectively. A relatively low percentage (16.3%) reported adverse events, which may or may not have been drug related, and there were few reports (10.7%) of gastric complaints. Twenty-seven (3.6%) patients withdrew from the study for reasons not specified.

Adult↗
PubMed1982

[The significance of structural glycoproteins, demonstrated by the example of the fibronectins. Biochemical principles and clinical use].

Fibronectin, a structural glycoprotein on cell surfaces, appears in significant concentrations too in human blood plasma. Fibronectin influences cell interactions and cell growth and is an essential part of the extracellular matrix. The following review summarizes the biochemistry and function of fibronectin--or rather of fibronectins, bearing in mind the difference in protein structure between plasma fibronectin and cell surface fibronectin. Fibronectin is identical with one opsonin (alpha 2-opsonic glycoprotein). During shock and septicemia it undergoes a marked decrease. The diminished concentration in the plasma indicates a reduced function of the reticulo-endothelial system. A report is given on initial substitution trials.

Cell Membrane↗
PubMed1981

[Reduced plasma fibronectin in patients with sepsis and shock (author's transl)].

Plasma fibronectin concentrations were determined in 16 patients with sepsis and shock. In all patients a definite decrease was observed during the course of the disease which did not correlate with coagulative function. Fibronectin in plasma rose to normal levels with improvement in the clinical picture. It is possible that plasma fibronectin indicates the functioning of the reticuloendothelial system.

Adult↗
PubMedDate not supplied

[Interactions of non-steroidal antirheumatic drugs with oral antidiabetic agents: acemetacin--glibenclamide].

In a double-blind cross-over trial on 20 diabetic patients of type IIb we investigated whether a drug interaction between glibenclamide and acemetacin may possibly occur. After hospitalization of all in-patients needing glibenclamide therapy, a one-week period of adaptation to clinical conditions with optimized diet, antidiabetic dosage of the drug and the beginning of a diabetes learning programme followed. Thereafter, in a randomized design, ten out of the 20 patients were treated concomitantly with either 60 mg acemetacin t.i.d. or placebo for 1 week. Furthermore, a cross-over period of one week's duration followed once more. Daily blood glucose profiles (four values) were measured every second day and suggested a continuous improvement of the severe diabetic state previously seen. Blood glucose levels reached an optimal steady-state condition after 1 week of adaptation. Concomitant treatment with acemetacin did not lead to a relevant alteration of the laboratory parameters used in type IIb diabetic patients. This could also be established due to HbA1 values. Contrary to other nonsteroidal anti-inflammatory drugs, interactions between acemetacin and the widely used oral antidiabetic glibenclamide could not be established.

Anti-Inflammatory Agents, Non-Steroidal↗